MX348831B - Administración parenteral de tapentadol. - Google Patents

Administración parenteral de tapentadol.

Info

Publication number
MX348831B
MX348831B MX2013010046A MX2013010046A MX348831B MX 348831 B MX348831 B MX 348831B MX 2013010046 A MX2013010046 A MX 2013010046A MX 2013010046 A MX2013010046 A MX 2013010046A MX 348831 B MX348831 B MX 348831B
Authority
MX
Mexico
Prior art keywords
tapentadol
parenteral administration
pharmaceutical composition
value
acceptable salt
Prior art date
Application number
MX2013010046A
Other languages
English (en)
Other versions
MX2013010046A (es
Inventor
Schiene Klaus
Christoph Thomas
Bloms-Funke Petra
Schiller Marc
Karine Katrien Inghelbrecht Sabine
Carolus Augusta Embrechts Roger
Reinhold Ulrich
Wulsten Eva
Feil Ulrich
Original Assignee
Gruenenthal Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Gruenenthal Gmbh filed Critical Gruenenthal Gmbh
Publication of MX2013010046A publication Critical patent/MX2013010046A/es
Publication of MX348831B publication Critical patent/MX348831B/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P23/00—Anaesthetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12—Carboxylic acids; Salts or anhydrides thereof

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Dermatology (AREA)
  • Emergency Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Engineering & Computer Science (AREA)
  • Pain & Pain Management (AREA)
  • Anesthesiology (AREA)
  • Rheumatology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

La invención se refiere a una composición farmacéutica acuosa adaptada para la administración parenteral de tapentadol o una sal fisiológicamente aceptable del mismo que tiene un valor de pH de al menos.
MX2013010046A 2011-03-04 2012-03-02 Administración parenteral de tapentadol. MX348831B (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201161449317P 2011-03-04 2011-03-04
EP11003602 2011-05-03
PCT/EP2012/000905 WO2012119728A1 (en) 2011-03-04 2012-03-02 Parenteral administration of tapentadol

Publications (2)

Publication Number Publication Date
MX2013010046A MX2013010046A (es) 2013-12-16
MX348831B true MX348831B (es) 2017-06-30

Family

ID=44653043

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2013010046A MX348831B (es) 2011-03-04 2012-03-02 Administración parenteral de tapentadol.

Country Status (23)

Country Link
US (3) US20120225951A1 (es)
EP (2) EP3025710A1 (es)
JP (4) JP2014510067A (es)
KR (2) KR101970468B1 (es)
CN (2) CN107088226A (es)
AU (2) AU2012224953C1 (es)
BR (1) BR112013022213A2 (es)
CA (1) CA2828635C (es)
CY (1) CY1117426T1 (es)
DK (1) DK2680833T3 (es)
EA (2) EA024193B1 (es)
ES (1) ES2573414T3 (es)
HK (1) HK1194964A1 (es)
HR (1) HRP20160400T1 (es)
HU (1) HUE027514T2 (es)
IL (1) IL227825A (es)
MX (1) MX348831B (es)
PL (1) PL2680833T3 (es)
PT (1) PT2680833E (es)
RS (1) RS54711B1 (es)
SI (1) SI2680833T1 (es)
WO (1) WO2012119728A1 (es)
ZA (1) ZA201306479B (es)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8846765B2 (en) 2010-06-15 2014-09-30 Gruenenthal Gmbh Pharmaceutical combination
EP2680832B1 (en) 2011-03-04 2019-09-04 Grünenthal GmbH Aqueous pharmaceutical formulation of tapentadol for oral administration
NO2736501T3 (es) * 2011-07-29 2018-05-19
BR112015009839A2 (pt) * 2012-11-01 2017-07-11 Torrent Pharmaceuticals Ltd composição farmacêutica de tapentadol para administração parenteral
EP2808319A1 (en) 2013-05-31 2014-12-03 Arevipharma GmbH 3-[3-(Dimethylamino)-1-ethyl-2-methylpropyl]phenol resin complex
EP2845625A1 (en) 2013-09-04 2015-03-11 Grünenthal GmbH Tapentadol for use in the treatment of fibromyalgia and chronic fatigue syndrome
CN103735500B (zh) * 2014-01-28 2016-01-20 江苏华泽医药科技有限公司 盐酸他喷他多注射液及其制备方法
MX2017012312A (es) * 2015-03-27 2018-01-18 Gruenenthal Gmbh Formulacion estable para administracion parenteral de tapentadol.
KR20190057349A (ko) * 2016-09-23 2019-05-28 그뤼넨탈 게엠베하 타펜타돌의 비경구 투여용 안정한 제제
WO2018153947A1 (en) 2017-02-23 2018-08-30 Grünenthal GmbH Tapentadol as local anesthetic
EP4011369A1 (en) * 2020-12-14 2022-06-15 G.L. Pharma GmbH Aqueous pharmaceutical composition comprising tapentadol tartrate

Family Cites Families (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8334422D0 (en) * 1983-12-23 1984-02-01 Sterwin Ag Composition
DE4426245A1 (de) 1994-07-23 1996-02-22 Gruenenthal Gmbh 1-Phenyl-3-dimethylamino-propanverbindungen mit pharmakologischer Wirkung
US6399087B1 (en) * 2000-12-20 2002-06-04 Amphastar Pharmaceuticals, Inc. Propofol formulation with enhanced microbial inhibition
DE10109763A1 (de) * 2001-02-28 2002-09-05 Gruenenthal Gmbh Pharmazeutische Salze
JP4905616B2 (ja) * 2001-04-19 2012-03-28 ライオン株式会社 ソフトコンタクトレンズ用点眼剤
PE20030527A1 (es) 2001-10-24 2003-07-26 Gruenenthal Chemie Formulacion farmaceutica con liberacion retardada que contiene 3-(3-dimetilamino-1-etil-2-metil-propil) fenol o una sal farmaceuticamente aceptable del mismo y tabletas para administracion oral que la contienen
US20030191187A1 (en) * 2002-04-01 2003-10-09 Lee Fang Yu Injectable pharmaceutical composition containing a non-steroidal anti-inflammatory drug and method for preparing the same
US20040180915A1 (en) * 2003-03-14 2004-09-16 Xanodyne Pharmacal, Inc. Methadone-containing compositions for parenteral administration and method of use thereof
DK1612203T3 (da) * 2004-06-28 2007-12-03 Gruenenthal Gmbh Krystallinske former af (-)-(1R,2R)-3-(3-dimethylamino-1-ethyl-2-methylpropyl)-phenolhydrochlorid
CA2572352A1 (en) 2004-07-01 2006-01-12 Gruenenthal Gmbh Oral dosage form safeguarded against abuse containing (1r,2r)-3-(3-dimethylamino-1-ethyl-2-methyl-propyl)phenol
WO2006116626A2 (en) * 2005-04-28 2006-11-02 Theraquest Biosciences Llc Methods and compositions for treating pain
CN101431990B (zh) 2006-04-28 2011-08-03 格吕伦塔尔有限公司 包含3-（3-二甲基氨基-1-乙基-2-甲基-丙基）-酚和对乙酰氨基酚的药物结合
EP2012763B1 (en) 2006-04-28 2011-03-23 Grünenthal GmbH Pharmaceutical combination comprising 3- (3-dimethylamin0-1-ethyl-2-methyl-pr0pyl) -phenol and an nsaid
CA2656696C (en) * 2006-07-24 2013-06-11 Janssen Pharmaceutica N.V. Preparation of (2r,3r)-3-(3-methoxyphenyl)-n,n,2-trimethylpentanamine
EP1905440A1 (de) * 2006-09-06 2008-04-02 Boehringer Ingelheim Pharma GmbH & Co. KG Verwendung einer pharmazeutischen Zusammensetzung enthaltend ein Anticholinergikum zur Abtötung von Mikroorganismen und zur Behandlung von Atemwegsinfektionen
TWI394564B (zh) * 2006-09-21 2013-05-01 Alcon Res Ltd 自行保存型水性藥學組成物
DE102007012165A1 (de) * 2007-03-12 2008-09-18 Grünenthal GmbH Verwendung von 1-Phenyl-3-dimethylamino-propanverbindungen zur Therapie des Neuropathieschmerzes
JP2008266168A (ja) * 2007-04-18 2008-11-06 Teika Seiyaku Kk 眼科用剤
EP1985292A1 (en) * 2007-04-23 2008-10-29 Grünenthal GmbH Titration of tapentadol
MX2010005680A (es) 2007-11-23 2010-12-21 Protect Pharmaceutical Corp Composiciones de tapentadol.
WO2009092601A1 (en) 2008-01-25 2009-07-30 Grünenthal GmbH Pharmaceutical dosage form
KR101641519B1 (ko) * 2008-09-05 2016-07-21 그뤼넨탈 게엠베하 3-（3-디메틸아미노-1-에틸-2-메틸-프로필）-페놀과 항간질제의 약제학적 병용물
EP2246044A1 (en) * 2009-04-21 2010-11-03 Pierre Fabre Dermo-Cosmétique Paediatric solutions comprising a beta-blocker
US20100272815A1 (en) * 2009-04-28 2010-10-28 Actavis Group Ptc Ehf Amorphous form of tapentadol hydrochloride

Also Published As

Publication number Publication date
HUE027514T2 (en) 2016-10-28
ES2573414T3 (es) 2016-06-07
EA028149B1 (ru) 2017-10-31
AU2012224953A1 (en) 2013-09-19
CA2828635A1 (en) 2012-09-13
SI2680833T1 (sl) 2016-06-30
EA024193B1 (ru) 2016-08-31
US20160106688A1 (en) 2016-04-21
HK1194964A1 (zh) 2014-10-31
JP2014510067A (ja) 2014-04-24
RS54711B1 (en) 2016-08-31
JP2022033863A (ja) 2022-03-02
PL2680833T3 (pl) 2016-08-31
KR20180064568A (ko) 2018-06-14
JP2018021050A (ja) 2018-02-08
CN103501775A (zh) 2014-01-08
JP6837944B2 (ja) 2021-03-03
KR101970468B1 (ko) 2019-04-19
US20120225951A1 (en) 2012-09-06
EP3025710A1 (en) 2016-06-01
ZA201306479B (en) 2014-05-28
WO2012119728A1 (en) 2012-09-13
EP2680833A1 (en) 2014-01-08
IL227825A (en) 2017-07-31
DK2680833T3 (en) 2016-05-23
EP2680833B1 (en) 2016-03-02
AU2012224953B2 (en) 2017-01-05
CY1117426T1 (el) 2017-04-26
US20200215003A1 (en) 2020-07-09
JP2023075244A (ja) 2023-05-30
EA201300990A1 (ru) 2014-02-28
EA201600088A1 (ru) 2016-07-29
CN107088226A (zh) 2017-08-25
KR101903351B1 (ko) 2018-10-04
KR20140017587A (ko) 2014-02-11
AU2017202214B2 (en) 2019-02-14
CA2828635C (en) 2020-01-14
BR112013022213A2 (pt) 2017-05-02
IL227825A0 (en) 2013-09-30
MX2013010046A (es) 2013-12-16
AU2012224953C1 (en) 2017-07-13
PT2680833E (pt) 2016-06-09
AU2017202214A1 (en) 2017-04-27
HRP20160400T1 (hr) 2016-05-20

Similar Documents

Publication Publication Date Title
MX2013010046A (es) Administracion parenteral de tapentadol.
PH12015501993A1 (en) Pyrazole-amide compound and medicinal uses therefor
MX344473B (es) Composicion farmaceutica acuosa semisolida que contiene tapentadol.
UA105229C2 (uk) Фармацевтичний склад
EA201300989A1 (ru) Водная фармацевтическая композиция тапентадола для перорального введения
IN2014DN10670A (es)
MY160727A (en) Oral formulations and lipophilic salts of methylnaltrexone
MY187718A (en) Pharmaceutical formulations
MX2014004196A (es) Citramida de rasagilina.
CY1115556T1 (el) Φαρμακευτικη συνθεση για χορηγηση απο το στομα η οποια περιλαμβανει ετεξιλικη δαβιγατρανη
MX340983B (es) Composiciones farmaceuticas y nutraceuticas de acido abscisico.
MX2014010433A (es) Nueva forma cristalina de sulfato de sitagliptina.
MX2016001422A (es) Composicion farmaceutica de fingolimod.
TN2014000060A1 (en) Benzothiazolone compound
UA115072C2 (uk) Похідні гідантоїну
MD4615C1 (ro) Formă solidă izolată de monoclorhidrat de anamorelin, compoziţie farmaceutică şi procedeu de fabricare a formei de dozare farmaceutice care o conţine
MX2011011899A (es) Metodo para reducir los niveles proteicos ubiquitinados.
TN2015000058A1 (en) Salts of benzothiazolone compound as beta-2-adrenoceptor agonist
MX355103B (es) Composicion para el tratamiento de desordenes inflamatorios e inmunes.
WO2012108794A3 (ru) Производные 1,2,4-триазол-з-илтиогликолевой кислоты для применения в терапии
IN2013DE00880A (es)
WO2013035997A3 (en) Pharmaceutical composition for preventing or treating alopecia comprising tianeptine or its salt
UA111066C2 (uk) Композиція, яка містить шелак та/або його сіль і натрію крохмальгліколят

Legal Events

Date Code Title Description
FG Grant or registration